home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Oncology Clinical Development Congress

 
  May 22, 2012  
     
 
Oxford Global, London
10-11 oct 2012


The Event

In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 50 speakers will present a full conference programme covering the topics outlined below.

Day 1 – Clinical Development

  • Establishing acceptable endpoints
  • Developing targeted therapies
  • Strategic partnerships
  • Innovation in clinical imaging
  • Co-development of combined therapies
  • Avoiding late-stage failures

Day 2 – Clinical Trials

  • Increasing efficiency through trial design
  • Trials in emerging markets
  • Comparative trials
  • Regulation and compliance
  • Adaptive trial designs
  • Clinical outsourcing
  • Patient recruitment and retention
  • CRO relationship management
  • Operational challenges
 
 
Organized by: Oxford Global
Invited Speakers:
  • Philip Arlen
    President & CEO, Neogenix Oncology
  • Samuel Blackman
    Director, Oncology Early Clinical Development, GlaxoSmithKline
  • Alton Boynton
    CSO, Northwest Biotherapeutics
  • Qinhua Cindy Ru
    Clinical Trial Head, Novartis
  • Robert Coleman
    Professor of Medical Oncology and Associate Director of the National Cancer Research Network
  • Silvia Corretge
    Clinical Research Oncology, Boehringer Ingelheim
  • Laura Cove-Smith
    University of Manchester
  • Birgit Gaschler-Markefski
    Head of German Clinical Biostatistics Group Oncology, Boehringer Ingelheim Pharma GmbH&Co. KG
  • Sven Gogov
    Senior Global Clinical Leader – Oncology, Novartis
  • Christopher Hart
    Clinical Information Science Director, AstraZeneca
  • Victoria John
    Head of Clinical Partnerships, Cancer Research UK
  • Prash Krishna
    Associate Director - Clinical Development, Eisai
  • Robert Lechleider
    Senior Director, Human Genome Sciences
  • Frédéric Levy
    Associate Director, Research & Evaluation, Debiopharm
  • Howard Mellor
    Drug Safety Scientist, AstraZeneca
  • Robert Morgan
    SVP Regulator Affairs, Ziopharm
  • Martin Picard
    Senior Medical Director, Head Cilengitide, Global Clinical Development Unit Oncology, Merck
  • Ruth Plummer
    Clinical Professor of Experimental Cancer Medicine, Newcastle University
  • Justine Reise
    Senior Clinical Trials Manager-Oncology, Imperial College London
  • Senior Representative
    Northwest Biotherapeutics
  • Marie Anne Stager
    Director, Clinical Operations, Seattle Genetics
  • Eric Towler
    Director, Global Project Management & Leadership, Daiichi Sankyo
  • Helgi Van De Velde
    Senior Director Oncology Clinical Research, Johnson & Johnson
  • Bob Wellings
    Clinical Biomarker Scientist, AstraZeneca
 
Deadline for Abstracts: Ended
 
Registration:

Early Bird Discounts Available!

Please Contact Celia Coules at c.coules@oxfordglobal.co.uk for more information, to requent the agenda and for registration details

E-mail: c.coules@oxfordglobal.co.uk
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.